Showing results (71-80 of 194) with videos related to
Sort By:
Pageof 20
Nature Communications|June 20, 2017
Lipid-mediated PX-BAR domain recruitment couples local membrane constriction to endocytic vesicle fissionJohannes Schöneberg, Martin Lehmann, Alexander Ullrich, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 6, 2004
Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homingKarin Reif, Klaus Okkenhaug, Takehiko Sasaki, et al.Molecular & Cellular Proteomics : MCP|May 2, 2012
Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistanceMaria P Alcolea, Pedro Casado, Juan-Carlos Rodríguez-Prados, et al.The Biochemical Journal|December 14, 2011
Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressorInma M Berenjeno, Julie Guillermet-Guibert, Wayne Pearce, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 4, 2006
The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cellsKlaus Okkenhaug, Daniel T Patton, Antonio Bilancio, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 15, 2009
The p110delta isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cellsDong Liu, Tingting Zhang, Aaron J Marshall, et al.Blood|November 16, 2014
Platelet PI3Kβ and GSK3 regulate thrombus stability at a high shear ratePierre-Alexandre Laurent, Sonia Séverin, Béatrice Hechler, et al.Molecular Biology of the Cell|August 5, 2011
Syndecan-2 is a novel ligand for the protein tyrosine phosphatase receptor CD148James R Whiteford, Xiaojie Xian, Claire Chaussade, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 6, 2007
Requirement for phosphoinositide 3-kinase p110delta signaling in B cell antigen receptor-mediated antigen presentationMonther M Al-Alwan, Klaus Okkenhaug, Bart Vanhaesebroeck, et al.Nature Reviews. Drug Discovery|March 30, 2026
A renaissance in targeting the PI3K/AKT/mTOR pathwaySarah E Conduit, Neil Vasan, Jennifer R Brown, et al.Pageof 20